At a glance
- Originator GlaxoSmithKline
- Developer Nonindustrial source
- Class Antiplatelets
- Mechanism of Action Platelet aggregation inhibitors; Thromboxane A2 synthase inhibitors; Thromboxane receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Ischaemic heart disorders; Peripheral vascular disorders; Stroke